Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio reported positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial, with bempikibart demonstrating a 35.3% mean reduction in SALT score and 40% of patients achieving SALT-20 response. The company completed a $200 million public offering in July 2026, bringing total cash to $106.3 million as of June 30, 2026, sufficient to fund operations through Phase 3 topline results. Q2 net loss improved to $8.9 million from $9.5 million year-over-year, driven by lower R&D expenses following the sale of the ADX-097 program in November 2025.
Key figures
- Revenue
- 0
- Revenue Yoy
- 0
- Net loss
- 8900000
- Ga expenses
- 4900000
- Rd expenses
- 4300000
- Offering proceeds
- 200000000
- Cash and equivalents
- 106300000
- Salt score reduction
- 35.3%
- Salt 20 response rate mitt
- 40.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.